Literature DB >> 23600716

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases.

Anamarija M Perry1, David Crockett, Bhavana J Dave, Pamela Althof, Lisa Winkler, Lynette M Smith, Patricia Aoun, Wing C Chan, Kai Fu, Timothy C Greiner, Phillip Bierman, Robert Gregory Bociek, Julie M Vose, James O Armitage, Dennis D Weisenburger.   

Abstract

B-cell lymphoma, unclassifiable (B-UCL), with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, is a poorly characterized entity. Therefore, we investigated cases of B-UCL treated by the Nebraska Lymphoma Study Group (NLSG). We searched the NLSG registry for years 1985-2010 for cases of B-UCL. Immunohistochemical stains and fluorescence in situ hybridization studies for MYC, BCL2 and BCL6 gene rearrangements were performed. Among the 39 cases studied, 54% were male and 46% were female, with a median age of 69 years. The majority of patients presented with advanced-stage disease (62%) and had high (3-5) International Prognostic Index (IPI) scores (54%). The median overall survival (OS) was only 9 months and the 5-year OS was 30%. Patients with low IPI scores (0-2) had a better survival than those with high scores (3-5). The cases were genetically heterogeneous and included 11 'double-hit' lymphomas with rearrangements of both MYC and BCL2 or BCL6. None of the immunohistochemical or genetic features was predictive of survival. This B-cell lymphoma is a morphologically-recognizable entity with a spectrum of genetic abnormalities. New and better treatments are needed for this aggressive lymphoma.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23600716     DOI: 10.1111/bjh.12343

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  30 in total

Review 1.  Management of Patients with MYC-Altered Lymphomas.

Authors:  Daniel J Landsburg
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

2.  Diagnostic challenges in a case of B cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.

Authors:  Chi-Chiu So; Ka-Hung Yung; Man-Leng Chu; Thomas S K Wan
Journal:  Int J Hematol       Date:  2013-10       Impact factor: 2.490

3.  The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.

Authors:  Katrin S Hüttl; Annette M Staiger; Julia Richter; M Michaela Ott; Sabrina Kalmbach; Wolfram Klapper; Anne-Sophie Biesdorf; Lorenz Trümper; Andreas Rosenwald; Marita Ziepert; Heike Horn; German Ott
Journal:  Virchows Arch       Date:  2021-03-02       Impact factor: 4.064

4.  Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma.

Authors:  Dominic P Decker; Pamela C Egan; Adam S Zayac; Diana O Treaba; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2019-08-21

5.  miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.

Authors:  Michalina Zajdel; Grzegorz Rymkiewicz; Magdalena Chechlinska; Katarzyna Blachnio; Barbara Pienkowska-Grela; Beata Grygalewicz; Krzysztof Goryca; Maria Cieslikowska; Zbigniew Bystydzienski; Pawel Swoboda; Jan Walewski; Jan Konrad Siwicki
Journal:  Tumour Biol       Date:  2015-02-13

6.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Authors:  Daniel J Landsburg; Marissa K Falkiewicz; Adam M Petrich; Benjamin A Chu; Amir Behdad; Shaoying Li; L Jeffrey Medeiros; Ryan D Cassaday; Nishitha M Reddy; Martin A Bast; Julie M Vose; Kimberly R Kruczek; Scott E Smith; Priyank Patel; Francisco Hernandez-Ilizaliturri; Reem Karmali; Saurabh Rajguru; David T Yang; Joseph J Maly; Kristie A Blum; Weiqiang Zhao; Charles Vanslambrouck; Chadi Nabhan
Journal:  Br J Haematol       Date:  2016-07-29       Impact factor: 6.998

7.  Clinicopathological Analysis of B Cell Lymphomas, Unclassifiable; with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma in a Tertiary Care Hospital in Southern India.

Authors:  Subramanian Kalaivani Selvi; Rakhee Kar; Debdatta Basu; Sajini Elizabeth Jacob; Biswajit Dubashi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-30       Impact factor: 0.900

8.  Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.

Authors:  Ken-Ichi Miyamoto; Yukio Kobayashi; Akiko Miyagi Maeshima; Hirokazu Taniguchi; Junko Nomoto; Hideaki Kitahara; Suguru Fukuhara; Wataru Munakata; Dai Maruyama; Kensei Tobinai
Journal:  Int J Hematol       Date:  2016-04-19       Impact factor: 2.490

Review 9.  The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.

Authors:  Pei Lin; L Jeffrey Medeiros
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

10.  Mandibular sporadic Burkitt lymphoma in an adult patient: A case report and review of the literature.

Authors:  Nahal Azimi; Farnoosh Razmara; Samira Derakhshan; Neda Kardouni Khoozestani
Journal:  Clin Case Rep       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.